# CELESTIAL - Phase 3 Pivotal Trial



of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma

The CELESTIAL global phase 3 clinical trial tested the effects of cabozantinib compared with placebo in patients with advanced hepatocellular carcinoma (HCC) who had already received treatment with sorafenib (Nexavar®), the standard of care for first-line HCC treatment. The main objective of the CELESTIAL trial was to determine whether cabozantinib can improve survival in this patient population.

# ► WHAT IS HEPATOCELLULAR CARCINOMA (HCC)?

- HCC is the most common type of liver cancer.<sup>1</sup>
- In 2017, it is estimated that nearly 41,000 new cases will be diagnosed and approximately 29,000 people will die from HCC in the U.S.<sup>2</sup>
- This type of liver cancer is the third leading cause of cancer-related deaths worldwide.<sup>3</sup>

Cabozantinib is not indicated for the treatment of advanced HCC.

#### **MEDIA CONTACT**

Lindsay Treadway Public Affairs and Advocacy Relations Exelixis, Inc.

(650) 837-7522 ltreadway@exelixis.com



## GLOBAL PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLINDED, INTERNATIONAL TRIAL

- Designed to compare cabozantinib with placebo in 760 patients ages 18 years and older with advanced HCC whose disease had spread or grown after treatment with sorafenib (Nexavar®), the standard of care for first-line treatment of advanced HCC.
- Patients had received up to two prior systemic cancer therapies for HCC and had adequate liver function.
- Conducted at more than 100 sites in 19 countries

#### PATIENTS WERE RANDOMLY ASSIGNED TO:

- · Oral cabozantinib 60 mg tablet once daily
- · A placebo tablet once daily

#### **STUDY ENDPOINTS:**

## Primary endpoint

 Overall survival: average length of time from randomization until death from any cause

### Secondary endpoint

- Objective response rate: percentage of patients whose tumors respond to treatment (complete or partial confirmed response)
- **Progression-free survival:** time until either death or disease worsening, per investigator review

**For additional information on the study,** visit www.Celestialclinicaltrial.com or https://clinicaltrials.gov